Blue light-based therapy for TIIDM and obesity-associated metabolic deficits: Intense blue light therapy increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 27/April/2018, 11.32 pm